Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.90
13 pages

Dendritic Cells in Cancer Immunotherapy

Matthias Gunzer
Department of Dermatology, University of Munster, Germany
Stephan Grabbe
Department of Dermatology, University of Munster, Germany

ABSTRAKT

Antigen presentation is a critical regulatory element for the induction of cellular immune responses. Thus, one of the principal current goals of tumor immunotherapy is to control and enhance tumor antigen presentation. In this respect, dendritic cells (DC) are now being widely investigated as immunotherapeutic agents for the treatment of disseminated malignancies. At present, numerous ways to employ DCs for tumor immunotherapy are being tested, ranging from direct in situ expansion and activation of DCs to adoptive transfer of ex vivo generated DCs, and numerous techniques have been designed to optimize DC activation, tumor antigen delivery to DCs, and induction of tumor-specific, as well as helper immune responses, in vivo. However, the results of recent preclinical studies and the diversity of the clinical phase I trials that are currently underway indicate that little is still known about the exact mechanisms by which DCs modulate tumor immunity and pose the concern that premature clinical trials might not yield the desired results and might be harmful to, rather than promote, the concept of DC-based tumor immunotherapy. This review summarizes some of the current approaches to induce tumor immunity by DC-based vaccination and discusses their advantages and concerns.


Articles with similar content:

Therapeutic Dendritic Cell−Based Cancer Vaccines: The State of the Art
Critical Reviews™ in Immunology, Vol.33, 2013, issue 6
Marius M. Strioga, Valerijus Ostapenko, Daniel J. Powell Jr., Neringa T. Dobrovolskiene, Virgil E. J. C. Schijns, Thomas Felzmann, Jaroslav Michalek, Miroslava Matuskova
NK Cells in Therapy of Cancer
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 1-2
Veronika Bachanova, Jeffrey S. Miller
Microenvironmental Hypoxia Orchestrating the Cell Stroma Cross Talk, Tumor Progression and Antitumor Response
Critical Reviews™ in Immunology, Vol.31, 2011, issue 5
Muhammad Zaeem Noman, Yosra Messai, Thibault Carre, Salem Chouaib, Bassam Janji, Meriem Hasmim, Intissar Akalay, Marine Meron
Dendritic Cell Editing by Natural Killer Cells
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 1-2
Guido Ferlazzo, Lorenzo Moretta
CD1d-Mediated Antigen Presentation to Natural Killer T (NKT) Cells
Critical Reviews™ in Immunology, Vol.23, 2003, issue 5-6
Tonya J. Roberts, Venkataraman Sriram, Yinling Lin, Sungyoo Cho, Randy R. Brutkiewicz, Yu Kyeong Hwang